Month: July 2022

Vertex, whose VX-880 stem cell therapy for type 1 diabetes has cleared clinical proof of concept, is acquiring ViaCyte, a private biotech that has also reached clinical trials with its own stem cell therapy. In the $320 million all-cash deal, Vertex will acquire ViaCyte’s human stem cell lines, manufacturing facilities, and other relevant intellectual property.…